EyePoint, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Kirby McInerney LLP is investigating EyePoint Pharmaceuticals (NASDAQ: EYPT) for potential securities fraud. The probe follows the company's Phase 3 trial failure for DURAVYU, which caused its stock to drop 67% on August 17, 2026. CEO Jay S. Duker had previously expressed confidence in the trial results. The firm is seeking information from investors.
EyePoint Pharmaceuticals (EYPT) shares fell ~70% after DURAVYU failed to meet the primary endpoint in the Phase 3 LUGANO trial for wet age-related macular degeneration. The company reported favorable secondary results, including a 42% reduction in treatment burden. Levi & Korsinsky is investigating potential securities fraud claims on behalf of EYPT investors who lost money.
US stocks are mixed, with chipmakers and AI-infrastructure stocks rising, while software companies decline. Treasury Secretary Bessent announced upcoming economic measures against Iran. S&P 500 is tracking for 32% Q2 earnings growth, with 85% of companies beating estimates. Marvell (MRVL) and Sandisk (SNDK) lead gains, while Datadog (DDOG) and Salesforce (CRM) lead losses. Astera Labs (ALAB) and Onto Innovation (ONTO) received upgrades, while EyePoint (EYPT) plunged after a failed trial.
Over the past 7 days, alphai's AI scored 2 news stories mentioning EYPT (EyePoint, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent EYPT coverage spans market movers, regulation and technology.
In the last 30 days, EYPT insiders filed 1 SEC Form 4 transaction — 1 purchase ($52K) and no sales. The most active reporter was Zaderej Karen L. with 1 filing.
Potential fraud investigation could trigger further share decline and heightened short interest.
The trial failure is a material negative catalyst likely to pressure the stock further.
Material clinical-trial failure drives a high-conviction negative repricing risk.
A major late-stage trial failure is a decisive, company-specific negative catalyst for EYPT.
An insider open-market purchase by a director is a modest bullish signal, but it is not a fundamental catalyst like earnings or guidance.
alphai scores every news story that mentions EYPT with an AI model for sentiment and relevance, and aggregates insider trades from EyePoint, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Kirby McInerney LLP is investigating EyePoint Pharmaceuticals (NASDAQ: EYPT) for potential securities fraud. The probe follows the company's Phase 3 trial failure for DURAVYU, which caused its stock to drop 67% on August 17, 2026. CEO Jay S. Duker had previously expressed confidence in the trial results. The firm is seeking information from investors.
2 min readEyePoint Pharmaceuticals (EYPT) shares fell ~70% after DURAVYU failed to meet the primary endpoint in the Phase 3 LUGANO trial for wet age-related macular degeneration. The company reported favorable secondary results, including a 42% reduction in treatment burden. Levi & Korsinsky is investigating potential securities fraud claims on behalf of EYPT investors who lost money.
2 min readUS stocks are mixed, with chipmakers and AI-infrastructure stocks rising, while software companies decline. Treasury Secretary Bessent announced upcoming economic measures against Iran. S&P 500 is tracking for 32% Q2 earnings growth, with 85% of companies beating estimates. Marvell (MRVL) and Sandisk (SNDK) lead gains, while Datadog (DDOG) and Salesforce (CRM) lead losses. Astera Labs (ALAB) and Onto Innovation (ONTO) received upgrades, while EyePoint (EYPT) plunged after a failed trial.
6 min readStock indices fluctuated as chipmakers rose while software companies declined. S&P 500 Q2 earnings are tracking at +32% growth, with AI infrastructure contributing 60%. Sandisk (SNDK) led gains, up +10%, while Datadog (DDOG) led losses, down -3%. EyePoint (EYPT) dropped -71% after a failed trial. Constellation Brands (STZ) fell -5% after Berkshire Hathaway sold its stake.
6 min readZaderej Karen L. purchased 10,600 shares of EyePoint, Inc. (EYPT) at $4.93 on 2026-08-18.
2 min readEyePoint Pharmaceuticals (EYPT) reported that its phase III study for Duravyu in wet age-related macular degeneration (wet AMD) missed the primary endpoint, causing shares to drop 67%. The study did not show non-inferiority to Regeneron's (REGN) Eylea in the full dataset, but Duravyu met key secondary endpoints, including a 42% reduction in treatment burden. The company plans to present additional data and awaits results from a second phase III study, LUCIA, expected in Q4 2026. EYPT shares have
5 min readAnalyst actions: DA Davidson upgraded Duolingo (DUOL) to Buy, PT $160 (from $130). Citi upgraded Bath & Body Works (BBWI) to Buy, PT $25. KeyBanc upgraded Acadia Realty Trust (AKR) to Overweight, PT $25. Mizuho downgraded Norwegian Cruise Line (NCLH) to Neutral, PT $17 (from $22). Multiple other upgrades/downgrades and initiations were issued across retail, real estate, telecom, and healthcare.
4 min readEyePoint Inc. (EYPT) shares fell again in pre-market after a Phase 3 wet AMD trial setback. RBC Capital downgraded EYPT to Sector Perform from Outperform and cut its price target about 86% to $5, citing Duravyu’s failure to meet the primary endpoint versus aflibercept. RBC and H.C. Wainwright said regulatory and clinical uncertainty could persist; results expected in Q4.
4 min readU.S. stocks closed lower on Monday. The Dow Jones fell 0.51%, the S&P 500 declined 0.52%, and the Nasdaq Composite dropped 0.32%, with weakness in Consumer Goods, Consumer Services, and Financials. Nike fell 4.11%, while Caterpillar rose 2.93%. Oil rose, and investors awaited Fed minutes and retail earnings.
4 min readEyePoint, Inc. (EYPT) shares fell about 69% after topline results from the LUGANO Phase 3 trial of DURAVYU in wet age-related macular degeneration missed the primary endpoint. The stock traded around $4.585 on Monday versus a prior close of $14.75. An ad hoc analysis excluding a 4% cohort suggested non-inferiority to on-label aflibercept.
2 min read
